Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

896.53 +33.67 (+3.90%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
S&P 500 Earnings Season Concludes with Robust Performance, Signaling Corporate Resilience
As the curtain falls on another corporate earnings season, the S&P 500 has delivered a performance that has largely exceeded initial expectations, painting a picture of surprising corporate health... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Unusual volume S&P500 stocks in Monday's session
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded following a decline the previous week. The stock had dropped sharply the... 
Via StockStory
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
3 Top Stocks to Load Up on After Earnings
Here are three stocks to buy now that could offer investors upside in the short and long terms. 
Via The Motley Fool
Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio?
Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly. 
Via Benzinga
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Eli Lilly and Company reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines. However, shares of Eli Lilly stock tumbled 14%. Here are ETFs with... 
Via Talk Markets
Topics ETFs
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. 
Via MarketBeat
Topics Government World Trade
Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Trump's Gold Tariffs Shake Markets, Eli Lilly Plunges, Oil Dips On US-Russia Deal, Jobs Miss Fuels Recession Fears — This Week In Economy
The past week saw market turbulence, with President Trump's new gold tariffs, Eli Lilly's dramatic stock drop, a weakening jobs report fueling recession fears, and a divided Federal Reserve debating... 
Via Benzinga
Topics Economy Government World Trade
Why Novo Nordisk Stock Flew Higher on Friday
It looked good next to a company that has been stealing its thunder lately. 
Via The Motley Fool
Why Eli Lilly Stock Sank 18% This Week
The drugmaker is in a 35% drawdown. 
Via The Motley Fool
Topics World Trade
Apple Notches Best Week In Years, Trump Shakes Fed Leadership: This Week In Markets
After a dip last week, Wall Street rebounded as earnings remained strong. Tech stocks surged, but Eli Lilly struggled. Trump imposed tariffs on India and nominated Stephen Miran for Fed seat. 
Via Benzinga
Topics Economy Government World Trade
Wall Street's Resilient Rally: What's Driving the Positive Momentum
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
Expert Outlook: Eli Lilly Through The Eyes Of 4 Analysts
 
Via Benzinga
Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst
Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength. 
Via Benzinga
In today's session, there are S&P500 stocks with remarkable trading volume.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone. 
Via MarketBeat
SoundHound Stock Rallies On Huge Revenue Jump
SoundHound stock rallied Friday after the conversational AI technology company posted a huge gain in revenue. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Does This $856 Million Investment Make Eli Lilly Stock a Buy?
The drugmaker continues to grab headlines for all the right reasons. 
Via The Motley Fool
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
Eli Lilly has normally been a market-beating stock, but not this year. 
Via The Motley Fool
Topics Economy World Trade
Apple's $704 Billion Decade-Long Buybacks Exceed Market Cap Of All But 13 Companies Worldwide
Apple's $704B in buybacks over 10 years exceeds the market cap of 488 S&P 500 firms. Learn why it still avoids major acquisitions. 
Via Benzinga
Topics Stocks
Stock Market Today: S&P 500, Nasdaq 100 Futures Rise As Trump Appoints New Fed Governor—Beauty Health, RealReal, Twilio In Focus On Q2 Earnings
U.S. stock futures rose on Friday after ending on a mixed note on Thursday. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Economy Government Stocks
Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?
Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide. 
Via Benzinga
Dow Tumbles Over 200 Points Following Earnings Reports: Fear & Greed Index Remains In 'Neutral' Zone
CNN's Fear & Greed Index declined but remained in Neutral zone on Thursday. Dow fell 200 points, while Apple, Eli Lilly reported earnings. 
Via Benzinga
Topics Stocks
Market Monitor News August 08 BMO - Tariffs, Tablets, and Turbulence: Wall Street Sways Under Trade War Fears and Pharma Fallout
Wall Street ended Thursday on a shaky note as disappointing drug trial results, new trade tariffs, and cautious corporate guidance weighed on sentiment. While Apple (AAPL | +3.2%) basked in the glow of... 
Via Chartmill
Topics World Trade
The Trade Desk, SoundHound AI, Eli Lilly, Block And CrowdStrike: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70 
Via Benzinga
Topics Artificial Intelligence
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
Via Stocktwits
Eli Lilly Stock Sell-Off ‘Overdone’ As Weight-Loss Pill Remains ‘Commercially Viable’
Eli Lilly's late-stage data for weight-loss pill falls short of expectations. 
Via Talk Markets
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.